Otilonio Qualigen (Otilonium Bromide)

Otilonium bromide, the active ingredient in Otilonio Qualigen, is an antispasmodic presented as a tablet for oral use. It relieves gastrointestinal smooth‑muscle spasms in adults with functional bowel disorders.

GNH USA supplies Otilonio Qualigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Otilonium bromide is used to manage disorders of the gastrointestinal tract that involve smooth‑muscle hyperactivity. - Irritable bowel syndrome: reduces abdominal pain and cramping associated with bowel habit irregularities. - Functional intestinal dysmotility: improves transit and eases discomfort caused by abnormal motility. - Spastic colon syndrome: lessens colonic spasms and associated urgency.

Adverse reactions to Otilonium bromide are generally mild and infrequent.

Common Side Effects: - Nausea: occasional mild stomach upset. - Headache: transient mild headache. - Dizziness: brief episodes of light‑headedness. - Dry mouth: reduced salivation. - Constipation: mild slowing of bowel movements.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, swelling, or difficulty breathing. - Severe dizziness or syncope: sudden loss of consciousness. - Cardiac arrhythmia: irregular heartbeat reported in isolated cases.

When prescribing Otilonium bromide, clinicians should consider several safety aspects. - Renal impairment: adjust use if severe kidney dysfunction is present. - Hepatic impairment: use cautiously in patients with liver disease. - Elderly patients: monitor for increased sensitivity to antispasmodic effects. - Concomitant anticholinergics: may enhance dry‑mouth sensation. - Pregnancy and lactation: only use if clearly needed; risk‑benefit must be evaluated. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Otilonium bromide may interact with other medicines that influence smooth‑muscle tone or cardiac conduction.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase systemic exposure. - Anti‑arrhythmic drugs: additive risk of cardiac rhythm disturbances.

Moderate Interactions (Monitor Closely): - Other antispasmodics: may potentiate anticholinergic side effects. - Diuretics: can enhance orthostatic hypotension. - Antihistamines: may increase dizziness or sedation.